{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:57:41Z","timestamp":1789721861173,"version":"4.0.1"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The impact of respiratory syncytial virus (RSV) is increasingly being recognized in older adults, however economic burden data is sparse. This study describes the burden of RSV and associated direct and indirect costs in adults aged 60\u202f+\u202fyears in real-world clinical practice across five European countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were drawn from the Adelphi RSV Disease Specific Program (DSP\u2122), a cross-sectional survey of physicians and patients in France, Germany, Italy, Spain, and the United Kingdom conducted December 2023\u2013June 2024. Patients aged 60\u202f+\u202fwith a confirmed RSV diagnosis were included. Physicians provided data on resource use and supportive care needs, and patients on paid and unpaid productivity loss. Country-specific unit costs were used to calculate direct and indirect costs. Patients were stratified by symptom duration from onset (acute- [A-]RSV: &amp;lt;4, ongoing- [O-]RSV: 4\u2013\u202f&amp;lt;\u202f12, and post-acute- [P-]RSV: 12\u201352\u202fweeks) and need for hospitalization (hospitalized [H-]RSV). All analyses were descriptive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Physicians (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f682) provided data on 1,581 patients with RSV (15.0% A-RSV, 12.4% O-RSV, 37.2% P-RSV, and 35.4% H-RSV). For their current RSV infection, patients had a mean of 4.3 visits to any healthcare provider (A-RSV: 3.1\u2013H-RSV: 4.6). H-RSV patients received nearly four times as many tests as A-RSV patients, with 54.8% receiving drugs (versus &amp;lt;37% in other subgroups). Overall, 87.4% of H-RSV patients stayed in hospital overnight (mean stay duration: 7.2 nights). Of all patients, 36.8% required supportive care, with 93.3\u201398.4% receiving non-professional care. Mean overall work impairment was 53.0% (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f24), with 18.0% of the 373 patients who responded reporting unpaid productivity loss. Mean direct costs per patient ranged from \u20ac320\u2013\u20ac6,900 for A-RSV and H-RSV respectively, with hospitalization driving costs in H-RSV. Drug costs trended higher with disease duration. The indirect cost of supportive care was consistent across groups (\u20ac140\u2013\u20ac191), meanwhile paid productive loss cost was between \u20ac52\u2013\u20ac797 and unpaid productivity loss between \u20ac25\u2013\u20ac415 in A-RSV and P-RSV, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>RSV poses a high economic burden in older adults across disease stages, increasing numerically with symptom duration and need for hospitalization, highlighting a need for prevention and continued monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1773556","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:51:20Z","timestamp":1773903080000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Resource use and economic burden of respiratory syncytial virus among older adults in real-world clinical practice across five European countries"],"prefix":"10.3389","volume":"14","author":[{"given":"Diana","family":"Mendes","sequence":"first","affiliation":[{"name":"Pfizer Ltd.","place":["Tadworth, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lucas","sequence":"additional","affiliation":[{"name":"Adelphi Real World","place":["Bollington, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Quinones","sequence":"additional","affiliation":[{"name":"Adelphi Real World","place":["Bollington, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Li","sequence":"additional","affiliation":[{"name":"Adelphi Real World","place":["Bollington, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Fievez","sequence":"additional","affiliation":[{"name":"Pfizer France","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Lade","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Di Virgilio","sequence":"additional","affiliation":[{"name":"Pfizer Italia","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"L\u00f3pez-Ib\u00e1\u00f1ez de Aldecoa","sequence":"additional","affiliation":[{"name":"Pfizer S.L.U, Alcobendas","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Piercy","sequence":"additional","affiliation":[{"name":"Adelphi Real World","place":["Bollington, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Holbrook","sequence":"additional","affiliation":[{"name":"Adelphi Real World","place":["Bollington, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Sato","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["Collegeville, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.3390\/pathogens11111324","article-title":"Going viral-Rsv as the neglected adult respiratory virus","volume":"11","author":"Busack","year":"2022","journal-title":"Pathogens"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s40121-023-00792-3","article-title":"Adjusting for case under-ascertainment in estimating Rsv hospitalisation burden of older adults in high-income countries: a systematic review and modelling study","volume":"12","author":"Li","year":"2023","journal-title":"Infect Dis Ther"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"36384703","DOI":"10.1183\/16000617.0105-2022","article-title":"Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries","volume":"31","author":"Nguyen-Van-Tam","year":"2022","journal-title":"Eur Respir Rev"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/13696998.2024.2389676","article-title":"Economic burden of respiratory syncytial virus in adults in Germany \u2013 a health claims analysis between 2015 and 2018","volume":"27","author":"Huebbe","year":"2024","journal-title":"J Med Econ"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2174\/187152612800100116","article-title":"Respiratory syncytial virus infection in adult populations","volume":"12","author":"E Walsh","year":"2012","journal-title":"Infect Dis Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e70097","DOI":"10.1111\/irv.70097","article-title":"Estimated incidence rate of specific types of cardiovascular and respiratory hospitalizations attributable to respiratory syncytial virus among adults in Germany between 2015 and 2019","volume":"19","author":"Liang","year":"2025","journal-title":"Influenza Other Respir Viruses"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/cid\/ciab595","article-title":"Incidence of respiratory syncytial virus infection among hospitalized adults, 2017\u20132020","volume":"74","author":"Branche","year":"2022","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.jacc.2018.02.013","article-title":"Respiratory syncytial virus and associations with cardiovascular disease in adults","volume":"71","author":"Ivey","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/biomedicines11010071","article-title":"Cardiovascular complications of viral respiratory infections and Covid-19","volume":"11","author":"Franczuk","year":"2022","journal-title":"Biomedicine"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"100965","DOI":"10.1016\/j.lanepe.2024.100965","article-title":"Healthcare costs related to respiratory syncytial virus in paediatric intensive care units in the Netherlands: a nationwide prospective observational study (the brick study)","volume":"43","author":"Phijffer","year":"2024","journal-title":"Lancet Regional Health \u2013 Europe"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1016\/j.vaccine.2023.03.024","article-title":"Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: a multi-country prospective cohort study in Europe","volume":"41","author":"Mao","year":"2023","journal-title":"Vaccine"},{"key":"ref12","first-page":"126512","article-title":"Economic burden of children hospitalized with respiratory syncytial virus infection in Spain, 2016-2019","volume-title":"Vaccine","author":"Haeberer","year":"2025"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12916-025-03970-x","article-title":"Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: a multi-country analysis","volume":"23","author":"Li","year":"2025","journal-title":"BMC Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e1182","DOI":"10.1093\/infdis\/jiae314","article-title":"Incidence of Rsv in adults: a comprehensive review of observational studies and critical gaps in information","volume":"230","author":"Doty","year":"2024","journal-title":"J Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"126683","DOI":"10.1016\/j.vaccine.2024.126683","article-title":"Hospitalization cost estimates of respiratory syncytial virus and influenza infections in adults in Spain, 2016\u20132019","volume":"46","author":"Haeberer","year":"2025","journal-title":"Vaccine"},{"key":"ref16","year":"2025"},{"key":"ref17","year":"2025"},{"key":"ref18","year":"2025"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","article-title":"Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on disease specific programmes","volume":"39","author":"Anderson","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"A728","DOI":"10.1016\/j.jval.2014.08.065","article-title":"Evidence for validity of a national physician and patient-reported survey in China and United Kingdom: the disease specific programme","volume":"17","author":"Babineaux","year":"2016","journal-title":"Value Health"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/dmso.S120101","article-title":"Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015","volume":"9","author":"Higgins","year":"2016","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/irv.12729","article-title":"Risk factors for hospitalized respiratory syncytial virus disease and its severe outcomes","volume":"14","author":"Cai","year":"2020","journal-title":"Influenza Other Respir Viruses"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s40121-024-01021-1","article-title":"Rsv risk profile in hospitalized adults and comparison with influenza and Covid-19 controls in Valladolid, Spain, 2010-2022","volume":"13","author":"Haeberer","year":"2024","journal-title":"Infect Dis Ther"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"PharmacoEconomics"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World medical association declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/infdis\/jiaa361","article-title":"Severe morbidity and short- and mid- to long-term mortality in older adults hospitalized with respiratory syncytial virus infection","volume":"222","author":"Tseng","year":"2020","journal-title":"J Infect Dis"},{"key":"ref28","volume-title":"Antimicrobial Resistance in the Eu\/Eea-a One Health Response","year":"2022"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"ii7","DOI":"10.1093\/jac\/dkab172","article-title":"Consumption of antibiotics in the community, European Union\/European economic area, 1997\u20132017","volume":"76","author":"Bruyndonckx","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e0285170","DOI":"10.1371\/journal.pone.0285170","article-title":"The economic burden of antibiotic resistance: a systematic review and Meta-analysis","volume":"18","author":"Poudel","year":"2023","journal-title":"PLoS One"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/diseases13030068","article-title":"Healthcare resource utilization and economic outcomes of RSV-hospitalized patients aged \u2265 60 years: a retrospective cohort study","volume":"13","author":"Puggina","year":"2025","journal-title":"Dent Discourse"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"ofaf528","DOI":"10.1093\/ofid\/ofaf528","article-title":"Incidence and burden of respiratory syncytial virus-associated hospitalizations among people 65 and older in France: a national hospital database study","volume":"12","author":"Marot","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1385439","DOI":"10.3389\/fmicb.2024.1385439","article-title":"Predictors of prolonged length of stay in adult patients with respiratory syncytial virus infections - a multi-center historical cohort study","volume":"15","author":"Malik","year":"2024","journal-title":"Front Microbiol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/cid\/ciy991","article-title":"Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults","volume":"69","author":"Ackerson","year":"2019","journal-title":"Clin Infect Dis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e556","DOI":"10.1002\/hsr2.556","article-title":"Rsv-associated hospitalization in adults in the USA: a retrospective chart review investigating burden, management strategies, and outcomes","volume":"5","author":"Walsh","year":"2022","journal-title":"Health Sci Reports"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/irv.12912","article-title":"Cost determinants among adults hospitalized with respiratory syncytial virus in the United States, 2017-2019","volume":"16","author":"Choi","year":"2022","journal-title":"Influenza Other Respir Viruses"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1093\/infdis\/jiad510","article-title":"Respiratory syncytial virus\u2013associated hospitalization in adults with comorbidities in 2 European countries: a modeling study","volume":"229","author":"Osei-Yeboah","year":"2024","journal-title":"J Infect Dis"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/1403494817726197","article-title":"How to understand informal caregiving patterns in Europe? The role of formal long-term care provisions and family care norms","volume":"46","author":"Verbakel","year":"2018","journal-title":"Scand J Public Health"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40121-024-00920-7","article-title":"Estimated respiratory syncytial virus-related hospitalizations and deaths among children and adults in Spain, 2016\u20132019","volume":"13","author":"Haeberer","year":"2024","journal-title":"Infect Dis Ther"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/infdis\/jiad012","article-title":"Underascertainment of respiratory syncytial virus infection in adults due to diagnostic testing limitations: a systematic literature review and Meta-analysis","volume":"228","author":"Onwuchekwa","year":"2023","journal-title":"J Infect Dis"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/infdis\/jiaa183","article-title":"Cost of hospitalization associated with respiratory syncytial virus infection versus influenza infection in hospitalized older adults","volume":"222","author":"Ackerson","year":"2020","journal-title":"J Infect Dis"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1016\/j.jval.2021.11.664","article-title":"Posc190 hospital utilization for elderly patients diagnosed with respiratory syncytial virus (RSV) versus influenza in the us","volume":"25","author":"Belk","year":"2022","journal-title":"Value Health"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/infdis\/jiad189","article-title":"Estimation of the number of respiratory syncytial virus\u2013associated hospitalizations in adults in the European Union","volume":"228","author":"Osei-Yeboah","year":"2023","journal-title":"J Infect Dis"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1016\/S2666-5247(23)00195-7","article-title":"First RSV vaccine approvals","volume":"4","author":"Venkatesan","year":"2023","journal-title":"Lancet Microbe"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S0140-6736(25)00346-0","article-title":"Early impact of RSV vaccination in older adults in England","volume":"405","author":"Mensah","year":"2025","journal-title":"Lancet"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/s1473-3099(25)00064-7","article-title":"Early evidence of RSV vaccination impact on hospitalisation rates of older people in Scotland","volume":"25","author":"Hameed","year":"2025","journal-title":"Lancet Infect Dis"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1773556\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:51:21Z","timestamp":1773903081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1773556\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":46,"alternative-id":["10.3389\/fpubh.2026.1773556"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1773556","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"article-number":"1773556"}}